repost of march 2006: why i am strong on this stoc, page-4

I would suggest you go back and do further research re your comments.

As i quoted earlier:

"On the results of the primary analysis, there is a 90% chance that the 1mg dose of
AOD9604 induces weight loss. On the secondary analysis, there is greater than a 99%
chance that the 1mg dose of AOD9604 induces weight loss. If the chance is greater than
an industry standard of 95% the result is considered to be “statistically significant”."

99% on the secondary endpoint - 90% on the primary endpoint - is VERY significant! You forget also this is designed like a phase 3 study where subjects incorporate diet/fitness into their program and as i have stated and as Jevalent has further detailed, will enhance results even more significantly.

The 300 trial subjects were comprised of men and women aged 30 to 65 years with a body mass index (or BMI, being weight in kg divided by the square of height in meters) of 35 or higher. Trial subjects received daily doses of AOD9604 or placebo in 0mg (placebo), 1mg, 5mg, 10mg, 20mg, or 30mg quantities. There were 50 subjects in each dose group. The average age of the trial participants was 44 years and their average weight was 122 kilograms (268 lbs). The trial was randomized, double blind and placebo-controlled.

An optimum does of 1mg is better not only from a cost standpoint but more importantly, "Metabolic’s previous animal and in vitro data indicated that doses above the optimum dose would be less effective. THIS IS CHARACTERISTIC WITH hGH ."

Re your 70c, i suggest you look more closely in how biotechs are valued, and in particular, the value of the obesity market and trading patterns of mpb) - xenical/meridia are the two current leading obesity drugs and despite all their gross side-effects, have a mrket of around 5-10bn. MBP on the other hand has none of those side-effects and potentially has a market of 50bn+.

Imagine on release of successful results how many big pharmas would be clammering all over themselves to get an exclusive licensing deal with mbp!

Will be an instant multi-bagger one would think!

Other option is they may choose to go phase 3 themselves to lock in more value and with a very high chance of all phase 3 trials going commercialised, the only direction the sp is heading is up!

Add to that their other phase ii trial in ACV1 for a pain killer drug and you will realise the value and potential in this! :)